Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide

27 Sept 2019

Abstract excerpt

Glioblastoma (GBM) is the most malignant glioma, with a median overall survival (OS) of 14-16 months. Temozolomide (TMZ) is the first-line chemotherapy drug for glioma, but whether TMZ should be withheld from patients with GBMs that lack O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is still under debate. DNA methylation profiling holds great promise for further stratifying the responses of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31611911
DOI: 10.3389/fgene.2019.00910

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to TemozolomidePMID 31611911Read ↗

Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter.Semantic proximity Read ↗

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.Semantic proximity Read ↗

Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.Semantic proximity Read ↗

Development and Validation of a Novel DNA Methylation-Driven Gene Based Molecular Classification and Predictive Model for Overall Survival and Immunotherapy Response in Patients With Glioblastoma: A Multiomic AnalysisSemantic proximity Read ↗

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of GlioblastomasSemantic proximity Read ↗

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Semantic proximity Read ↗

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma MultiformeSemantic proximity Read ↗

A novel DNA damage and repair-related gene signature to improve predictive capacity of overall survival for patients with gliomas.Semantic proximity Read ↗

Identification of an epigenetic prognostic signature for patients with lower‐grade gliomasSemantic proximity Read ↗

DNA methylation in glioblastoma: impact on gene expression and clinical outcomeSemantic proximity Read ↗

Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping ReviewSemantic proximity Read ↗

A microarray-based DNA methylation study of glioblastoma multiformeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.